ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
Entry into a Material Definitive Agreement
On January 10, 2019, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into a Third Lease Amendment (the “Amendment”) to the Lease (the “Lease”) between Dimension Therapeutics, Inc., a wholly-owned subsidiary of the Company, and Rivertech Associates II, LLC to which the Lease was assigned to the Company, the term was extended to December 31, 2023, and an additional 9,538 square feet of space was added to the Lease.The Amendment is effective as of December 31, 2018. The Lease, as amended by the Amendment, covers certain space located at 840 Memorial Drive, Cambridge, MA.
The foregoing description of the Amendment is qualified in its entirety by the full text of the Amendment, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
* * *
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
